| PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity M Gato-Cañas, M Zuazo, H Arasanz, M Ibañez-Vea, L Lorenzo, ... Cell reports 20 (8), 1818-1829, 2017 | 286 | 2017 |
| PD1 signal transduction pathways in T cells H Arasanz, M Gato-Cañas, M Zuazo, M Ibañez-Vea, K Breckpot, ... Oncotarget 8 (31), 51936, 2017 | 276 | 2017 |
| The intracellular signalosome of PD-L1 in cancer cells D Escors, M Gato-Cañas, M Zuazo, H Arasanz, MJ García-Granda, R Vera, ... Signal transduction and targeted therapy 3 (1), 26, 2018 | 232 | 2018 |
| Functional systemic CD 4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy M Zuazo, H Arasanz, G Fernández‐Hinojal, MJ García‐Granda, M Gato, ... EMBO molecular medicine 11 (7), e10293, 2019 | 165 | 2019 |
| Understanding LAG-3 signaling L Chocarro, E Blanco, M Zuazo, H Arasanz, A Bocanegra, ... International journal of molecular sciences 22 (10), 5282, 2021 | 106 | 2021 |
| PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer A Bocanegra, G Fernandez-Hinojal, M Zuazo-Ibarra, H Arasanz, ... International journal of molecular sciences 20 (7), 1631, 2019 | 85 | 2019 |
| Early detection of hyperprogressive disease in non-small cell lung cancer by monitoring of systemic T cell dynamics H Arasanz, M Zuazo, A Bocanegra, M Gato, M Martínez-Aguillo, I Morilla, ... Cancers 12 (2), 344, 2020 | 68 | 2020 |
| Resistance to PD-L1/PD-1 blockade immunotherapy. A tumor-intrinsic or tumor-extrinsic phenomenon? L Chocarro de Erauso, M Zuazo, H Arasanz, A Bocanegra, C Hernandez, ... Frontiers in Pharmacology 11, 441, 2020 | 63 | 2020 |
| Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy M Zuazo, M Gato-Cañas, N Llorente, M Ibañez-Vea, H Arasanz, G Kochan, ... Annals of translational medicine 5 (19), 2017 | 61 | 2017 |
| A core of kinase-regulated interactomes defines the neoplastic MDSC lineage M Gato-Cañas, XM de Morentin, I Blanco-Luquin, J Fernandez-Irigoyen, ... Oncotarget 6 (29), 27160, 2015 | 59 | 2015 |
| Systemic CD4 immunity as a key contributor to PD-L1/PD-1 blockade immunotherapy efficacy M Zuazo, H Arasanz, A Bocanegra, G Fernandez, L Chocarro, R Vera, ... Frontiers in Immunology 11, 586907, 2020 | 54 | 2020 |
| Clinical landscape of LAG-3-targeted therapy L Chocarro, E Blanco, H Arasanz, L Fernández-Rubio, A Bocanegra, ... Immuno-Oncology and Technology 14, 100079, 2022 | 52 | 2022 |
| Myeloid-derived suppressor cells in the tumor microenvironment: current knowledge and future perspectives M Ibáñez-Vea, M Zuazo, M Gato, H Arasanz, G Fernández-Hinojal, ... Archivum immunologiae et therapiae experimentalis 66 (2), 113-123, 2018 | 48 | 2018 |
| Cutting-edge: Preclinical and clinical development of the first approved lag-3 inhibitor L Chocarro, A Bocanegra, E Blanco, L Fernández-Rubio, H Arasanz, ... Cells 11 (15), 2351, 2022 | 37 | 2022 |
| Senescent CD4 T cells unequivocally identify primary resistance and risk of hyperprogression to PD-L1/PD-1 immune checkpoint blockade in lung cancer M Zuazo-Ibarra, H Arasanz, G Fernández-Hinojal, M Gato-Cañas, ... BioRxiv, 320176, 2018 | 32 | 2018 |
| Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies C Hernandez, H Arasanz, L Chocarro, A Bocanegra, M Zuazo, ... International journal of molecular sciences 21 (7), 2411, 2020 | 31 | 2020 |
| Circulating low density neutrophils are associated with resistance to first line anti-PD1/PDL1 immunotherapy in non-small cell lung cancer H Arasanz, AI Bocanegra, I Morilla, J Fernández-Irigoyen, ... Cancers 14 (16), 3846, 2022 | 25 | 2022 |
| Hyperprogressive disease: main features and key controversies H Arasanz, M Zuazo, A Bocanegra, L Chocarro, E Blanco, M Martínez, ... International journal of molecular sciences 22 (7), 3736, 2021 | 25 | 2021 |
| Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy M Zuazo, H Arasanz, A Bocanegra, L Chocarro, R Vera, D Escors, ... EMBO molecular medicine 12 (9), e12706, 2020 | 23 | 2020 |
| Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO2 Chromatography M Ibanez-Vea, H Huang, X Martinez de Morentin, E Perez, M Gato, ... Journal of proteome research 17 (3), 1172-1182, 2018 | 23 | 2018 |
